Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
This type doesnt provide any added vitamins or minerals
Diabetes Care 39(10):17021710
(Empagliflozin is one of the active drugs in Synjardy.) Its important to note that animal studies dont always predict what will happen in people
Mounjaro can cause bad breath due to changes in digestion, reduced saliva production, and metabolic shifts such as ketosis
![PDF] GLP-1 receptor agonists: a review of head-to-head clinical studies](https://figures.semanticscholar.org/d6e214df491bd874c451833804c97c101868701d/4-Figure2-1.png)